stockrow
Friday 6 November 2026
Export ZLAB’s income statement to Excel — free account
Zai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
24.69
2.09
+9.25%
Follow ZLAB
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.66 | 4.72 | 4.60 | 4.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(50.84) | (33.47) | (174.87) | (74.25) | |
P/B ratio |
5.22 | 3.50 | 3.15 | 2.70 | |
Price to Tangible BV |
6.20 | 4.09 | 3.57 | 3.04 | |
EV/Sales |
5.61 | 3.65 | 3.39 | 2.93 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.56) | (12.32) | (15.20) | (8.93) | |
EV/FCF |
(12.58) | (10.11) | (11.57) | (8.21) | |
Quick Ratio |
0.15 | 1.84 | 2.07 | 2.15 | |
Current Ratio |
2.04 | 2.13 | 2.40 | 2.45 | |
Net Debt/EBITDA |
0.00 | 6.50 | 8.19 | 8.75 | |
Debt/Assets |
24.65% | 22.15% | 19.51% | 17.45% | |
Debt/Equity |
0.45 | 0.39 | 0.32 | 0.29 | |
Asset Turnover |
0.40 | 0.40 | 0.40 | 0.39 | |
Operating CF/Net income |
1.25 | 1.25 | 0.23 | 0.52 | |
Capex/Depreciation |
0.00 | (0.52) | (8.74) | (0.50) | |
Interest Coverage |
(39.94) | (48.20) | (42.39) | (51.03) | |
Research and Development Expense of Revenue |
46.03% | 58.10% | 65.85% | 48.30% | |
Selling, General and Administrative Expense of Revenue |
64.76% | 68.55% | 65.32% | 57.24% | |
Intangible Assets out of Total Assets |
0.00 | 0.08 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
10.16% | 11.23% | 13.58% | 12.46% | |
Graham Net Nets |
0.14 | 0.21 | 0.25 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.49%) | (9.00%) | (8.61%) | (9.13%) | |
Free Cash Flow Yield |
(6.69%) | (7.65%) | (6.37%) | (8.49%) | |
Revenue per Share |
0.00 | 0.95 | 0.90 | 1.16 | |
Operating CF per Share |
0.00 | (0.57) | (0.11) | (0.24) | |
Capex per Share |
0.00 | (0.01) | (0.20) | (0.01) | |
Free Cash Flow per Share |
0.00 | (0.58) | (0.31) | (0.25) | |
Cash per Share |
— | 6.42 | 6.87 | 7.21 | |
Shareholders Equity per Share |
0.00 | 5.43 | 5.98 | 6.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 5.43 | 5.98 | 6.53 | |
Free Cash Flow |
(70.55) | (64.82) | (34.20) | (27.32) | |
Working Capital |
440.15 | 485.45 | 551.75 | 603.12 | |
Capital Expenditures |
(12.68) | (1.42) | (22.29) | (1.30) | |
Net Current Asset Value |
403.78 | 446.28 | 510.97 | 562.40 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.01 | 0.22 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
75.34 | 79.05 | 65.31 | 95.65 | |
Average Payables |
109.98 | 122.02 | 114.59 | 121.26 | |
Average Inventory |
76.21 | 76.30 | 69.51 | 57.31 | |
Average Assets |
1,091.42 | 1,119.45 | 1,134.53 | 1,179.07 | |
Average Common Equity |
661.61 | 699.39 | 736.37 | 778.20 |
Columns are period end dates · fundamentals updated 5 Nov 2026